Analysis of Injectable Ketamine Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
According to a new industry report released by Fact.MR, turnover of the global injectable ketamine market is analyzed at US$ 750 million in 2024 and is projected to expand at a double-digit CAGR of 16.4% to achieve a value of US$ 3.42 billion by the end of 2034.
Mental health disorders, such as anxiety, PTSD, and depression are becoming more common worldwide and are often unresponsive to traditional treatments. Injectable ketamine provides quick relief for several ailments; therefore, it is becoming an ideal choice for patients and medical professionals looking for efficient substitutes for conventional therapies. The medical community is accepting ketamine-based therapies as research shows that they are effective in treating chronic pain and treatment-resistant depression (TRD).
As a result of this acceptability, injectable ketamine is becoming more popular in psychiatric and pain treatment procedures. The availability of injectable ketamine is increasing due to the opening of ketamine clinics and specialized treatment facilities across the globe. These facilities specialize in treating individuals with serious mental health conditions, which helps ketamine therapies become more widely available and adopted.
North America is forecasted to lead in 2024 with 36.9% of the worldwide injectable ketamine market share. The market in the region is expanding because of the significant prevalence of mental health conditions, including treatment-resistant depression, anxiety, and PTSD, primarily in the United States. Strong medical facilities, advanced psychiatric treatment, and greater funding for mental health are all advantages for the region.
Based on the product, the demand for ketamine hydrochloride (ketamine HCL) injections is analyzed at US$ 734.96 million in 2024 due to their effectiveness in treating chronic pain issues and treatment-resistant mental health disorders. In contrast to standard antidepressants, which generally take weeks to show results, ketamine hydrochloride (HCl) offers patients with severe depression, PTSD, and anxiety quick relief, normally within hours.
| Report Attributes | Details |
|---|---|
| Injectable Ketamine Market Size (2024E) | US$ 750 Million |
| Forecasted Market Value (2034F) | US$ 3.42 Billion |
| Global Market Growth Rate (2024 to 2034) | 16.4% CAGR |
| North America Market Share (2024E) | 36.9% |
| Western Europe Market Value (2024E) | US$ 168.1 Million |
| South Asia & Pacific Market Growth Rate (2024 to 2034) | 19.7% CAGR |
| Ketamine Hydrochloride (Ketamine HCl) Injections Segment Value (2034F) | US$ 3.35 Billion |
| General Surgeries Segment Value (2034F) | US$ 1.33 Billion |
| Key Companies Profiled | Greenco Biologicals; BNM Organics; Troikaa Parenterals; Neon Laboratories; Samarth Pharma; Seqens; Pfizer; Sun Pharmaceuticals; Supriya Lifesciences; Taj Pharmaceuticals; Hengrui; Anhui Wanhe Pharmaceutical. |
The market is expected to witness growth owing to increasing number of surgeries, advanced technologies in drug delivery devices and rapid rise in aging population. Also, rising number of local manufacturers and increasing R&D activities in anesthetics are anticipated to boost the market development.
Factors like the rising prevalence of chronic diseases, the growing aging population, and rising utilization of anesthetics are projected to drive the market development. In addition, technological advancements support the development of the market.
The geriatric population is at higher risk of getting affected with chronic diseases like diabetes, CVD, and CRD that leads to rising interest in medical procedures. Accordingly, the rising aging population is additionally anticipated to drive the development of the market.
Rising number of minimally invasive surgical and diagnostic procedures that are carried out on an outpatient basis need a huge number of general anesthesia drugs. These general anesthesia drugs possibly influence the cost of care as well as the efficacy in these outpatient settings. In this manner, the injectable ketamine market is expected to show significant growth.
People over 65 years will be more susceptible to chronic diseases, because of which they are probably going to need more number of surgeries. As per a Population Reference Bureau report, published in 2016, the number of Americans 65 years or more is expected to be 98 million by 2060, and the share of the geriatric population from the total population is projected to be around 24%.
Additionally, the rising burden of cardiovascular diseases (CVD) which needs medical procedures is driving the development of the injectable ketamine market.
Also, the rising incidence of co-morbidities among the geriatric population leads to an increasing risk of surgical complications and toxicities associated with general anesthetics. The increase in the number of procedures and rising aging population that need anesthesia are some of the major factors that are leading to development of the market.
The US Injectable ketamine market is expected to observe a robust growth in the market owing it to the rise in number of surgeries and large number of manufacturers present in the market. Development of the market is high in the United States, boosted by growing risk of cardiac diseases and organ failures among baby boomers together with essential restructuring of the of the healthcare system in the United States.
Increasing adoption of advance business models aimed to developing novel methodologies like receiving faster drug approvals for lower time-to-market and more reliance on external partners, industry associations, and academia will keep on favoring the manufacturers operating in the country.
Europe is expected to be the second most lucrative region for the market owing to several factors. Certain factors boosting the market growth include a reduction in the cost of newly invented drugs, new approvals of anesthetic drugs, and an increasing number of surgeries.
In Europe, the surgeries performed each year is rising at a rapid rate. The rise in the number of surgeries being performed has a significant impact on the injectable ketamine market, as anesthetics are extensively used in all surgeries to lower pain during surgery.
Some of the leading manufacturers and suppliers of Injectable Ketamine include
The Injectable Ketamine market is highly competitive, with the presence of a few of major players available in global markets, and several small-scale players in regional markets. Key players are supporting widely in the research and development to manufacture advanced products.
Moreover, key players are adopting strategies, such as launching new products, partnerships, and acquisitions and mergers to consolidate their position in the market. Globally, they are involved in long term contracts with healthcare companies, and are involving into partnerships and strategic alliances with other players in several countries to extend their business.
How big is the injectable ketamine market in 2024?
The global market for injectable ketamine is estimated at US$ 750 million in 2024.
What is the demand growth projection for injectable ketamine?
Worldwide demand for injectable ketamine is forecasted to rise at a CAGR of 16.4% from 2024 to 2034.
Injectable Ketamine Market